Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.39 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2279443 | 0.93 | HTT (0.49) | HTTSMN1; SMN2MEN1ALDH1A1HPGD | |
| SCHEMBL3355462 | 0.89 | HTT (0.53) | HTTSMN1; SMN2MEN1ALDH1A1HPGD | |
| SCHEMBL3355255 | 0.86 | HTT (0.55) | HTTSMN1; SMN2MEN1ALDH1A1HPGD | |
| SCHEMBL3354717 | 0.82 | HTT (0.71) | HTTSMN1; SMN2MEN1ALDH1A1HPGD | |
| SCHEMBL30982466 | 0.82 | HTT (0.51) | HTTSMN1; SMN2MEN1ALDH1A1HPGD | |
| SCHEMBL30982820 | 0.82 | HTT (0.51) | HTTSMN1; SMN2MEN1ALDH1A1HPGD | |
| SCHEMBL30982659 | 0.82 | HTT (0.51) | HTTSMN1; SMN2MEN1ALDH1A1HPGD | |
| SCHEMBL3356971 | 0.80 | SMN1; SMN2 (0.51) | HTTSMN1; SMN2MEN1ALDH1A1HPGD | |
| SCHEMBL3361358 | 0.79 | HTT (0.46) | HTTSMN1; SMN2MEN1ALDH1A1HPGD | |
| SCHEMBL6196944 | 0.77 | HTT (0.48) | HTTSMN1; SMN2MEN1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076199-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRIDONE CARBOXYLIC ACIDS | GE HEALTHCARE AS (NO) | 2010-03-25 | — | — | US | disclosed |
| US-20100076199-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRIDONE CARBOXYLIC ACIDS | GE HEALTHCARE AS (NO) | 2010-03-25 | — | — | US | disclosed |
| US-20100076199-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRIDONE CARBOXYLIC ACIDS | GE HEALTHCARE AS (NO) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076199-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRIDONE CARBOXYLIC ACIDS | PNPO, PGD, PDXK | HTT 4051/4885SMN1; SMN2 2855/4885MEN1 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.